<DOC>
	<DOCNO>NCT01500772</DOCNO>
	<brief_summary>This study evaluate overall efficacy , safety profile triple combination therapy alisporivir ( ALV ; DEB025 ) plus peginterferon alfa-2a ( PEG ) ribavirin ( RBV ) patient chronic hepatitis C ( HCV ) genotype 1 fail prior treatment protease inhibitor ( PI ) .</brief_summary>
	<brief_title>Alisporivir With PEG RBV Protease Inhibitor ( PI ) Treatment Failure Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients chronic HCV genotype 1 infection previous PI treatment failure 2 . Three month minimum time last dose previous PI treatment first dose study medication Exclusion criterion : 1 . Use investigational drug time enrollment 2 . History hypersensitivity PEG RBV 3 . Any null nonresponders prior PEG/RBV treatment Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>PI treatment failure</keyword>
</DOC>